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Background: More and more preclinical studies support the idea that curcumin, a 
plant-derived natural polyphenol, could be a promising anti-cancer drug. However poor 
bioavailability has limited its efficacy in clinical trials, and plasma curcumin levels remain low 
despite patients taking gram doses of curcumin.  
Methods: This study aimed to evaluate the safety and pharmacokinetics of newly 
developed nanoparticle curcumin with increased water solubility (named THERACURMIN). 
Six healthy human volunteers were recruited and received THERACURMIN at a single oral 
dose of 150 mg. After an interval of two weeks, the same subjects then received 
THERACURMIN at a single dose of 210 mg. Plasma curcumin levels were measured at 0, 1, 
2, 4, 6, and 24 h after THERACURMIN intake using high performance liquid 
chromatography (HPLC).  
Results: One subject reported grade 1 diarrhea after intake of 150 mg THERACURMIN. No 
other toxicities were observed in this study. Cmax for THERACURMIN at 150 mg and 210 mg 
was 189 ± 48 and 275 ± 67 ng/ml (mean ± S.E.M.), respectively and the area under the 
curve for 24 h was estimated to be 2649 ± 350 and 3649 ± 430 ng/ml × h (mean ± S.E.M.), 
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respectively. The t1/2 was estimated to be 9.7 ± 2.1 h for 150 mg and 13.0 ± 3.3 h for 210 
mg. 
Conclusion: THERACURMIN can safely increase plasma curcumin levels in a dose 
dependent manner at least up to 210 mg without saturating the absorption system. To the 
best of our knowledge, THERACURMIN is the first nanoparticle formulation of curcumin 
which demonstrates improved bioavailability in human subjects. We believe this compound 
could be a promising tool when testing the potential anti-cancer effects of curcumin in 
clinical trials.   
 





Curcumin is derived from turmeric (Curcuma longa) and is a natural polyphenol. Curcumin 
has long been used as a food, coloring agent and traditional medicine. More and more data 
support the idea that this chemical could be a promising anti-cancer drug [1, 8, 31]. Several 
investigators, including ourselves, have tested plasma curcumin levels in clinical trials and 
reported that plasma levels remained low in spite of taking gram doses of curcumin [7, 10, 
14, 27]. Furthermore, more than 8 g of curcumin intake did not increase blood curcumin 
levels in healthy volunteers [34]. Thus, poor bioavailability is the major weak point of 
curcumin and has been the main hurdle for physicians seeking to verify the therapeutic 
efficacy of this promising agent in clinical trials. Therefore, many researchers are now 
focusing on improving its bioavailability through several approaches including innovative 
drug delivery systems (liposomes, nanoparticles and phospholipids) [2, 4, 6, 9, 11, 15, 17-19, 
22, 24, 26, 29, 30, 32], the use of adjuvants [28] or the development of new curcumin 
analogues [13, 20, 23]. One of these approaches, a nanoparticle-based drug delivery 
system, has now been widely used to improve water solubility of hydrophobic agents [3, 5, 
12, 21]. By applying this nanoparticle-based drug delivery system to curcumin, a new form 
of curcumin (THERACURMIN) has been developed. THERACURMIN has improved water 
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solubility with its mean particle size of 0.19 m, and oral administration of THERACURMIN 
demonstrated more than 30-fold higher bioavailability compared to that of conventional 
curcumin in rat models [25]. Furthermore, Cmax for THERACURMIN at 30 mg was 30 ng/ml, 
while it was lower than 2 ng/ml after 30 mg of conventional curcumin intake in healthy 
human subjects [25]. However, it was not determined whether higher doses of 
THERACURMIN could safely increase plasma curcumin levels in a dose dependent 
manner. 
Therefore, in this study we aimed to determine the safety and improved bioavailability of 
THERACURMIN at dose levels higher than 30 mg. 
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2. Materials and Methods 
2.1. Preparation of THERACURMIN 
THERACURMIN was provided by the Theravalues Corporation (Tokyo, Japan). 
THERACURMIN was prepared as follows. Firstly, gum ghatti, which mainly consists of 
polysaccharides obtained from the exudation of ghatti trees, was dissolved in water to make 
gum ghatti solution. Curcumin powder was mixed into this solution, and water and glycerin 
were added to adjust the weight. The mixture was ground using a wet grinding mill 
(DYNO-MILL®KDL, Willy A Bachofen AG), and then dispersed by a high-pressure 
homogenizer (Homogenizer 15MR-8TA, APV Gaulin). Stable THERACURMIN was 
obtained from this procedure. The particle size of THERACURMIN was measured by a laser 
diffraction scattering method using Microtrac MT-30000II (Microtrac Inc., Montgomeryville, 
USA). THERACURMIN consisted of 10% curcumin, 2% other curcuminoids such as 
demethoxycurcumin and bisdemethoxycurcumin, 46% glycerin, 4% gum ghatti, and 38% 
water. THERACURMIN was provided in capsule form and each capsule contained 30 mg of 
THERACURMIN.  
2.2. Clinical Trial Design 
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Six healthy human volunteers with normal organ function were recruited. None of the 
subjects were taking daily medications. They were asked to avoid all foods containing high 
concentrations of curcumin within one day before and one day after THERACURMIN intake. 
Initially, the six subjects received THERACURMIN at a single dose of 150 mg (level 0). 
Adverse events were graded based on the National Cancer Institute Common Toxicity 
Criteria version 3.0 [33]. Any grade 3 or higher adverse events were pre-defined as dose 
limiting toxicities (DLT). If the incidence of DLT was two or lower out of six subjects, then we 
planned to evaluate the safety of THERACURMIN at a single dose of 210 mg (level 1) in the 
same subjects without DLT at level 0 after an interval of two weeks. Blood samples (2 ml) 
were collected in tubes containing EDTA just before THERACURMIN intake (0 h) and at 1, 2, 
4, 6, and 24 h after THERACURMIN intake. The protocol was approved by the institutional 
review board at Kyoto University Hospital and registered in the University Hospital Medical 
Information Network (UMIN) Clinical Trial Registry (ID 000003488). All protocol procedures 
were carried out at Kyoto University Hospital. 




Plasma curcumin levels were measured as previously reported [14]. A 0.1 ml aliquot of each 
plasma sample was transferred to a 10 ml glass tube and then 0.11 ml of 0.1M sodium 
acetate buffer (pH 5.0) containing 1000 U β-glucuronidase was added. The resulting 
solutions were incubated to hydrolyze the curcumin conjugates at 37°C for 1 h. Following 
the addition of 10 μl of Internal Standard (IS) working solution (500 ng/ml), a 0.5 ml volume 
of chloroform was added as an extraction solvent. The sample was vortexed for 1 min 
followed by ultrasonic vibration for 15 min and then centrifugation at 1610g for 5 min. The 
organic layer was transferred to a 1 ml glass tube and evaporated to dryness using a 
centrifuge concentrator. The dried extract was reconstituted in 100 μl of 50% acetonitrile 
(MeCN) containing 0.05% formic acid (FA) and then centrifuged at 7700g for 10 min. A 10 μl 
aliquot of the supernatant from the reconstituted sample solution was injected into the 
chromatographic system. 
The high performance liquid chromatography – tandem mass spectrometry (HPLC-MS/MS) 
system consisted of Prominence micro-LC system (Shimadzu, Kyoto, Japan) and an API 
3200 tandem mass spectrometer (Applied Biosystems, CA, USA) with electrospray 
ionization (ESI). Samples were subjected to Atlantis T3 (2.1 x 150 mm, 3 μm) (Waters, 
Milford, USA) as a separation C-18 column using a gradient of binding solvent (0.05% 
FA/H2O) and elution solvent (0.05% FA/MeCN) at a flow rate of 0.2 ml/min and a column 
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temperature of 40°C. Separation of samples was conducted by a 35-min linear gradient 
(5-95% elution solvent). The mass spectrometer was operated under multiple reaction 
monitoring (MRM) mode with a collision energy of 23 eV for curcumin and 33 eV for 
mepronil. The transitions (precursor to product) monitored were m/z 369→285 for curcumin, 
270→119 for mepronil. Chromatograms were integrated using the ANALYST version 1.5 
software.  
Stock solutions of curcumin and mepronil were prepared at a concentration of 1000 ng/ml in 
methanol (MeOH). The stock solution of mepronil was further diluted with 55% MeOH to 
prepare a calibration standard at a concentration of 100 ng/ml. The stock solution of 
curcumin was further diluted with 62% MeOH to prepare a calibration standard at a 
concentration of 200 ng/ml. Curcumin solution (200 ng/ml) was diluted with 50% MeOH to 
prepare the following standard solutions: 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25.0, 50.0, and 100.0 
ng/ml. These solutions were mixed with IS solution (100 ng/ml) at a ratio of 1:1 to prepare 
IS-containing calibration samples of 0.2-100.0 ng/ml (curcumin) and 50 ng/ml (mepronil). 
Stock solution (1000 ng/ml) of mepronil was further diluted with MeOH to prepare the IS 
working solution at a concentration of 500 ng/ml. 
2.4. Pharmacokinetic analysis 
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Area under the curve (AUC) is calculated using the trapezoidal method. Maximum 
concentrations (Cmax) and Tmax are the observed values. The t1/2 value was calculated by 
dividing 0.693 by the terminal rate constant, which was derived from the slope of the natural 






3.1. Subjects and Adverse Events 
Six healthy Japanese volunteers consisted of five males and one female (mean age, 44 
years; range, 38-51 years; mean body mass index, 24.4; range 20.2-27.8). Only one subject 
(case 1, Table 1) reported Grade 1 diarrhea lasting from day 1 through day 4 after 150 mg of 
THERACURMIN intake. However diarrhea did not recur after the second, 210 mg dose of 
THERACURMIN in this subject. No other adverse events were observed in this study. 
3.2. Plasma concentration of total curcumin  
Figure 1 shows the size characterization of THERACURMIN using a laser diffraction 
scattering method and Figure 2 shows representative HPLC chromatograms of plasma after 
enzymatic hydrolysis. Peak plasma curcumin levels after 150 mg THERACURMIN intake 
ranged from 152 to 285 ng/ml and Cmax was 189 ± 48 ng/ml (mean ± S.E.M.), while peak 
plasma curcumin levels after 210 mg THERACURMIN intake ranged from 221 to 594 ng/ml 
and Cmax was 275 ± 67 ng/ml (mean ± S.E.M.) (Figure 3). The area under the curve for 24 h 
was estimated to be 2649 ± 350 and 3649 ± 430 ng/ml × h (mean ± S.E.M.), respectively. 
The t1/2 were estimated to be 9.7 ± 2.1 h for 150 mg and 13.0 ± 3.3 h for 210 mg. Total 




A number of preclinical studies have demonstrated that curcumin could be a promising 
anti-cancer drug [1, 8, 31]. However, poor bioavailability is the major weak point in its clinical 
application: plasma curcumin levels remain low in spite of taking gram doses of curcumin [7, 
10, 14, 16, 27, 28] (Table 2). Lao et al. conducted a dose escalation study of curcumin in 
twenty-four healthy volunteers and could detect plasma curcumin in only two subjects who 
took 10 g or 12 g of oral curcumin [16]. In another study by Garcea et al., only trace amounts 
of curcumin were detected after intake of 3.6 g oral curcumin [10]. Furthermore, intake of 
more than 8g curcumin per day was not acceptable to patients [7] and could not increase 
the blood curcumin levels, probably due to saturation of the absorption system [34]. 
Therefore, improving bioavailability is essential in order to see the potential benefits of 
curcumin in clinical studies.  
Nanoparticle-based drug delivery systems are suitable for improving water solubility of 
hydrophobic agents like curcumin, and various forms of nanoparticle curcumin have recently 
been synthesized [2, 6, 9, 11, 15, 22, 24, 26, 29, 30]. Bisht et al. have synthesized polymeric 
nanoparticle encapsulated curcumin composed of N-isopropylacrylamide, 
N-vinyl-2-pyrrolidone and poly-ethyleneglycol-monoacrylate and reported that the efficacy of 
this nanoparticle encapsulated curcumin was similar to that of conventional curcumin in vitro 
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and in vivo [6]. Shaikh et al. have also reported the improved bioavailability of curcumin with 
nanoparticle encapsulation in rat models [26]. Similarly, THERACURMIN has improved 
water solubility with its mean particle size of 0.19 m (Figure 1), and oral administration of 
THERACURMIN demonstrated more than 30-fold higher bioavailability compared to that of 
conventional curcumin in rat models. Cmax for THERACURMIN at 30 mg was 30 ng/ml, while 
it was lower than 2 ng/ml after 30 mg of conventional curcumin intake in healthy human 
subjects [25]. However, it was not determined whether higher doses of THERACURMIN 
could safely increase plasma curcumin levels in a dose dependent manner. Therefore, we 
proceeded to determine the safety and improved bioavailability of THERACURMIN at dose 
levels higher than 30 mg. 
With a dose of 150 mg of THERACURMIN, we observed a plasma curcumin level (189 ± 48 
ng/ml, mean ± S.E.M.), which compared well with the level observed after intake of 8g of 
conventional curcumin in our previous study in pancreatic cancer patients (134±70 ng/ml) 
[14], or in other previous studies using gram doses of curcumin (Table 2). Only one subject 
reported grade 1 diarrhea lasting for 4 days after 150mg of THERACURMIN intake and no 
DLT was observed. Therefore, we proceeded to evaluate a dose of 210 mg of 
THERACURMIN in the same subjects after an interval of 2 weeks. As expected, plasma 
curcumin levels increased in a dose dependent manner (275 ± 67ng/ml, mean±S.E.M.) 
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without saturating the absorption system. No adverse events including diarrhea, which was 
observed at a dose of 150 mg, were reported.  
Our current results demonstrate that THERACURMIN can safely increase the plasma 
curcumin level in a dose dependent manner at least up to 210 mg. In rat models, 
THERACURMIN was able to increase plasma curcumin levels in a dose dependent manner 
up to at least 80 mg/kg without increasing toxicity (unpublished data). This suggests that an 
intake of more than 210 mg THERACURMIN may be able to increase plasma curcumin 
levels higher without saturating the absorption system in human subjects and further studies 
are now underway to test this hypothesis.  
To the best of our knowledge, THERACURMIN is the first nanoparticle formulation which 
demonstrates improved bioavailability in human subjects. We believe this compound could 
be a promising tool when testing the potential anti-cancer effects of curcumin in clinical trials. 
Several clinical trials are now underway to evaluate the therapeutic efficacy of 
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Figure 1. Size characterization  of THERACURMIN using 













Figure 2. Representative examples of HPLC chromatograms  


























Figure 3. Time course of plasma curcumin levels after intake of 150 mg 
(solid line) and 210 mg (dashed line) THERACURMIN (n=6). Error bar 
represents S.E.M.
150mg 210mg
gender age BMI Cmax T1/2 (h) Tmax (h) AUC Cmax T1/2 (h) Tmax (h) AUC
case1 male 44 24.2 270 6.4 1.0 1791 594 9.3 2.0 3763
case2 male 40 20.2 247 13.3 2.0 3221 284 17.3 6.0 4455
case3 female 51 27.8 220 12.0 2.0 2048 290 6.8 2.0 2324
case4 male 47 25.7 152 5.4 6.0 2102 221 9.0 4.0 2503
case5 male 38 23.9 285 5.0 4.0 4048 324 9.4 6.0 4980
case6 male 44 24.7 171 15.8 6.0 2679 254 26.1 4.0 3863
Table 1. Characteristics and pharmacokinetic parameters of study subjects


















3.6 g/day 3 4 ± 0.2 ng/ml




3.6 g/day 3 below 1 ng/ml




8 g/day 5 134 ± 70 ng/ml
Sasaki et al. healthy volunteers 0.03 g/day*2 7 29.5± 13 ng/ml
Current study healthy volunteers 0.21 g/day*2 6 275 ± 67 ng/ml
*1Plasma curcumin was detected in only one subject.
*2THERACURMIN was used in these studies
Table 2. Comparison of the published studies reporting plasma 
curcumin levels in human subjects after oral intake of curcumin.
